Lexicon Pharmaceuticals (LXRX) Revenue & Revenue Breakdown
Lexicon Pharmaceuticals Revenue Highlights
Latest Revenue (Y)
$1.20M
Latest Revenue (Q)
$1.65M
Lexicon Pharmaceuticals Revenue by Period
Lexicon Pharmaceuticals Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $1.20M | 766.19% |
| 2022-12-31 | $139.00K | -53.36% |
| 2021-12-31 | $298.00K | -98.76% |
| 2020-12-31 | $24.00M | -92.55% |
| 2019-12-31 | $322.07M | 409.54% |
| 2018-12-31 | $63.21M | -30.03% |
| 2017-12-31 | $90.33M | 8.40% |
| 2016-12-31 | $83.34M | -35.90% |
| 2015-12-31 | $130.01M | 468.89% |
| 2014-12-31 | $22.85M | 928.53% |
| 2013-12-31 | $2.22M | 104.04% |
| 2012-12-31 | $1.09M | -41.10% |
| 2011-12-31 | $1.85M | -62.33% |
| 2010-12-31 | $4.91M | -54.13% |
| 2009-12-31 | $10.70M | -66.89% |
| 2008-12-31 | $32.32M | -35.51% |
| 2007-12-31 | $50.12M | -31.15% |
| 2006-12-31 | $72.80M | -3.81% |
| 2005-12-31 | $75.68M | 22.58% |
| 2004-12-31 | $61.74M | 44.12% |
| 2003-12-31 | $42.84M | 21.70% |
| 2002-12-31 | $35.20M | -88.48% |
| 2001-12-31 | $305.58M | 2013.47% |
| 2000-12-31 | $14.46M | 207.63% |
| 1999-12-31 | $4.70M | - |
Lexicon Pharmaceuticals generated $1.20M in revenue during NA 2023, up 766.19% compared to the previous quarter, and up 1.90% compared to the same period a year ago.
Lexicon Pharmaceuticals Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $1.65M | 45.75% |
| 2024-03-31 | $1.13M | 60.97% |
| 2023-12-31 | $702.00K | 333.33% |
| 2023-09-30 | $162.00K | -48.90% |
| 2023-06-30 | $317.00K | 1220.83% |
| 2023-03-31 | $24.00K | -14.29% |
| 2022-12-31 | $28.00K | -28.21% |
| 2022-09-30 | $39.00K | 11.43% |
| 2022-06-30 | $35.00K | -5.41% |
| 2022-03-31 | $37.00K | 164.29% |
| 2021-12-31 | $14.00K | -39.13% |
| 2021-09-30 | $23.00K | -90.17% |
| 2021-06-30 | $234.00K | 766.67% |
| 2021-03-31 | $27.00K | -86.43% |
| 2020-12-31 | $199.00K | -97.00% |
| 2020-09-30 | $6.63M | -27.60% |
| 2020-06-30 | $9.16M | 14.55% |
| 2020-03-31 | $8.00M | -8.34% |
| 2019-12-31 | $8.73M | -97.04% |
| 2019-09-30 | $294.45M | 2941.19% |
| 2019-06-30 | $9.68M | 5.06% |
| 2019-03-31 | $9.22M | -46.01% |
| 2018-12-31 | $17.07M | 148.99% |
| 2018-09-30 | $6.86M | -50.15% |
| 2018-06-30 | $13.75M | -45.44% |
| 2018-03-31 | $25.21M | -23.72% |
| 2017-12-31 | $33.05M | 22.66% |
| 2017-09-30 | $26.94M | 123.53% |
| 2017-06-30 | $12.05M | -34.11% |
| 2017-03-31 | $18.29M | -20.59% |
| 2016-12-31 | $23.04M | -16.88% |
| 2016-09-30 | $27.72M | 37.97% |
| 2016-06-30 | $20.09M | 60.79% |
| 2016-03-31 | $12.49M | -90.18% |
| 2015-12-31 | $127.28M | 22387.63% |
| 2015-09-30 | $566.00K | 50.53% |
| 2015-06-30 | $376.00K | -79.02% |
| 2015-03-31 | $1.79M | -91.66% |
| 2014-12-31 | $21.48M | 5026.97% |
| 2014-09-30 | $419.00K | -38.02% |
| 2014-06-30 | $676.00K | 144.04% |
| 2014-03-31 | $277.00K | -80.35% |
| 2013-12-31 | $1.41M | 492.44% |
| 2013-09-30 | $238.00K | 11.21% |
| 2013-06-30 | $214.00K | -40.56% |
| 2013-03-31 | $360.00K | 65.14% |
| 2012-12-31 | $218.00K | -41.40% |
| 2012-09-30 | $372.00K | 86.93% |
| 2012-06-30 | $199.00K | -33.67% |
| 2012-03-31 | $300.00K | -12.54% |
| 2011-12-31 | $343.00K | -3.38% |
| 2011-09-30 | $355.00K | -36.04% |
| 2011-06-30 | $555.00K | -6.88% |
| 2011-03-31 | $596.00K | -52.43% |
| 2010-12-31 | $1.25M | 60.44% |
| 2010-09-30 | $781.00K | -36.66% |
| 2010-06-30 | $1.23M | -24.86% |
| 2010-03-31 | $1.64M | 16.22% |
| 2009-12-31 | $1.41M | -33.74% |
| 2009-09-30 | $2.13M | -28.71% |
| 2009-06-30 | $2.99M | -28.29% |
| 2009-03-31 | $4.17M | -34.36% |
| 2008-12-31 | $6.35M | -15.47% |
| 2008-09-30 | $7.51M | -21.47% |
| 2008-06-30 | $9.57M | 7.57% |
| 2008-03-31 | $8.89M | -35.60% |
| 2007-12-31 | $13.81M | - |
Lexicon Pharmaceuticals generated $1.65M in revenue during Q2 2024, up 45.75% compared to the previous quarter, and up 6862.50% compared to the same period a year ago.
Lexicon Pharmaceuticals Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| MCRB | Seres Therapeutics | $126.33M | - |
| ARDX | Ardelyx | $124.46M | $73.22M |
| HOOK | HOOKIPA Pharma | $20.13M | - |
| MREO | Mereo BioPharma Group | $10.00M | - |
| BLRX | BioLineRx | $4.80M | $6.86M |
| LXRX | Lexicon Pharmaceuticals | $1.20M | $1.65M |
| IBRX | ImmunityBio | $622.00K | $1.05M |
| CWBR | CohBar | - | - |
| XFOR | X4 Pharmaceuticals | - | $563.00K |
| AVRO | AVROBIO | - | - |
| DAWN | Day One Biopharmaceuticals | - | $8.19M |
| GRTX | Galera Therapeutics | - | - |
| ELEV | Elevation Oncology | - | - |
| TERN | Terns Pharmaceuticals | - | - |
| OCEA | Ocean Biomedical | - | - |
| HEPA | Hepion Pharmaceuticals | - | - |
| ENVB | Enveric Biosciences | - | - |
| EFTR | eFFECTOR Therapeutics | - | - |
LXRX Revenue FAQ
What is Lexicon Pharmaceuticals’s yearly revenue?
Lexicon Pharmaceuticals's yearly revenue for 2023 was $1.2M, representing an increase of 766.19% compared to 2022. The company's yearly revenue for 2022 was $139K, representing a decrease of -53.36% compared to 2021. LXRX's yearly revenue for 2021 was $298K, representing a decrease of -98.76% compared to 2020.
What is Lexicon Pharmaceuticals’s quarterly revenue?
Lexicon Pharmaceuticals's quarterly revenue for Q2 2024 was $1.65M, a 45.75% increase from the previous quarter (Q1 2024), and a 419.56% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $1.13M, a 60.97% increase from the previous quarter (Q4 2023), and a 4608.33% increase year-over-year (Q1 2023). LXRX's quarterly revenue for Q4 2023 was $702K, a 333.33% increase from the previous quarter (Q3 2023), and a 2407.14% increase year-over-year (Q4 2022).
What is Lexicon Pharmaceuticals’s revenue growth rate?
Lexicon Pharmaceuticals's revenue growth rate for the last 3 years (2021-2023) was 304.03%, and for the last 5 years (2019-2023) was -99.63%.